rosiglitazone has been researched along with Atherogenesis in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 35 (54.69) | 29.6817 |
| 2010's | 27 (42.19) | 24.3611 |
| 2020's | 2 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, SL; Kim, H; McPherson, DD; Moody, MR; Yin, X | 1 |
| Gao, X; Li, J; Li, Q; Lu, G; Xiao, Y; Xie, D; Zhai, Y; Zhang, J | 1 |
| Dong, E; Li, QQ; Liao, WT; Liu, BR; Luo, H; Shen, YG; Tang, XQ; Wu, N; Yang, HS; Yang, Y; Yue, XZ; Zhang, GM | 1 |
| Bu, X; Duan, X; He, Y; Ming, X; Sun, S; Wu, Q; Yan, F; Zhu, H | 1 |
| Chai, BK; Dharmani, DM; Lau, YS; Loong, BJ; Mohankumar, SK; Rais, MM; Ting, KN | 1 |
| Bennett, PH; Crandall, JP; Edelstein, SL; Goldberg, RB; Kahn, SE; Knowler, WC; Mather, KJ; Mudaliar, S; Nathan, DM; Orchard, TJ; Temprosa, M; White, NH | 1 |
| Abdullah, SM; Ayers, CR; de Lemos, JA; Gada, E; Gore, MO; Khera, A; McGuire, DK; Owens, AW; Rohatgi, A; See, R | 1 |
| Anderson, JL; Keeley, MC; Smith, EC; Smith, SC; Taylor, RL | 1 |
| Sun, B; Yan, WJ; Zhang, WL; Zou, ZP | 1 |
| Chen, S; Lei, L; Li, H; Pan, S; Yan, F | 1 |
| Fan, YZ; Guo, ZG; Lai, WY; Li, C; Liu, TR; Tu, Y; Xie, D; Zhong, JK | 1 |
| Badgeley, MA; Bagalkot, V; Deiuliis, JA; Kampfrath, T; Maiseyeu, A; Rajagopalan, S | 1 |
| Du, X; Gao, M; Li, L; Liao, J; Liu, G; Qi, Y; Wang, M; Wang, Y; Yang, H | 1 |
| Haniu, H; Matsuda, Y; Murakmi-Murofushi, K; Tsukahara, T | 1 |
| Bian, S; Chen, G; Deng, M; Huang, L; Kang, H; Qiu, Y; Yang, J; Yu, J | 1 |
| Chu, Y; Fan, J; Lin, Y; Liu, E; Yang, P; Yu, Q; Zhang, C; Zhao, S | 1 |
| Chen, K; Liao, W; Pan, L; Wen, J; Xu, H; Zhou, M | 1 |
| Lehmann, DF; Lohray, BB | 1 |
| Derosa, G; Salvadeo, SA | 1 |
| Besler, C; Doerries, C; Giannotti, G; Landmesser, U; Lüscher, TF | 1 |
| Hennig, B; MacDonald, R; Oesterling, E; Shen, H; Stromberg, A; Toborek, M | 1 |
| Distrutti, E; Fiorucci, S; Mencarelli, A; Renga, B | 1 |
| Chen, FL; Hu, RM; Li, LX; Liang, WC; Liu, Y; Wang, XC; Yang, YH; Yang, ZH; Zhou, WB | 1 |
| Aprahamian, T; Bonegio, RG; Chiang, LK; Richez, C; Rifkin, IR; Sato, K; Walsh, K; Yasuda, K | 1 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Devergne, O; Heinz, P; Kempe, S; Kokai, E; Marx, N; Wirth, T | 1 |
| Fisher, M | 1 |
| Alméras, N; Angel, J; Batalla, N; Bertrand, OF; Costerousse, O; De Larochellière, R; Després, JP; Dzavik, V; Natarajan, M; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L; Title, L | 1 |
| Becker, L; Gharib, SA; Heinecke, JW; Irwin, AD; Oram, JF; Vaisar, T; Wijsman, E | 1 |
| Chaudhuri, A; Dandona, P; Ghanim, H | 1 |
| Alméras, N; Angel, J; Batalla, N; Bertrand, OF; Costerousse, O; De Larochellière, R; Després, JP; Dzavik, V; Natarajan, M; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L; Title, LM | 1 |
| Alessi, A; Baroncini, LA; Brofman, PR; França Neto, OR; Noronha, Ld; Précoma, DB; Prim, C; Silva, RF | 1 |
| Dhanjil, S; Godsland, IF; Johnston, DG; Pavitt, DV; Richmond, W; Yee, MS | 1 |
| Srivastava, RA | 1 |
| Li, Y; Liu, N; Ren, L; Sheng, Z; Tang, R; Zhi, H | 1 |
| Dai, SS; Fu, XH; He, FT; Li, GB; Li, J; Wu, GZ; Zeng, YJ; Zhong, D | 1 |
| Abdullah, WZ; Ibrahim, S; Mustaffa, N; Yusof, Z | 1 |
| Boesch-Saadatmandi, C; Döring, F; Gardemann, A; Graeser, AC; Höppner, W; Huebbe, P; Lippmann, J; Minihane, AM; Rimbach, G; Storm, N; Wagner, AE; Wiswedel, I | 1 |
| Bruedigam, C; Chiba, H; Eijken, M; Koedam, M; van Leeuwen, JP | 1 |
| Chang, CC; Chang, FR; Chang, WC; Du, YC; Hsieh, TJ; Liu, CS; Wu, YC | 1 |
| Chen, Y; Cheng, F; Fan, J; Li, Y; Liu, E; Wang, Y; Yu, Q; Zhao, S | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E | 1 |
| Chen, D; Chen, TJ; Chen, X; Fang, W; Lü, SZ; Mi, SH; Shi, Q; Song, AL; Wang, LY; Wang, W; Wu, Y; Xu, JP; Yan, D; Zhao, QM | 1 |
| Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G | 1 |
| Balletshofer, B; Häring, HU; Hetzel, J; Hombach, V; Koenig, W; Kratzer, W; Marx, N; Rittig, K; Walcher, D | 1 |
| Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Jandeleit-Dahm, KA; Lassila, M; Smith, CM | 1 |
| Os, I | 1 |
| Liu, XM; Luo, F; Wang, ZH | 1 |
| Baldi, A; Baldi, F; Cacciapuoti, F; Carbonara, O; Ceriello, A; Cirillo, F; Coppola, L; Crescenzi, B; D'Amico, M; D'Andrea, F; Di Filippo, C; Esposito, K; Giugliano, D; Marfella, R; Nicoletti, GF; Portoghese, M; Rossi, F; Sasso, FC; Siniscalchi, M; Verza, M | 1 |
| Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R | 1 |
| Adamiec, R; Bednarska-Chabowska, D; Dobosz, T; Gacka, M; Sadakierska-Chudy, A; Szymaniec, S | 1 |
| Allen, TJ; Calkin, AC; Jandeleit-Dahm, KA; Lassila, M; Thomas, MC; Tikellis, C | 1 |
| Balasubramani, M; Capps, N; Milles, J; Ramachandran, S; Shetty, C | 1 |
| Berglund, G; Hedblad, B; Janzon, L; Nilsson, P; Zambanini, A | 1 |
| Jezior, MR; Langley, RW; Stocker, DJ; Taylor, AJ; Vigersky, RA | 1 |
| Anderson, RG; Auwerx, J; Boucher, P; Herz, J; Li, WP; Matz, RL; Takayama, Y | 1 |
| Clancy, P; Golledge, J; Mangan, S | 1 |
| Hamilton, PK; Lockhart, CJ; McVeigh, GE; Quinn, CE | 1 |
| Atkin, SL; Cho, LW | 1 |
| Chin-Dusting, J; Cooper, ME; Jandeleit-Dahm, KA; Kling, D; Mizrahi, J; Murphy, A; Sebokova, E; Sheehy, K; Tikellis, C; Woollard, KJ | 1 |
| Honisett, SY; Komesaroff, PA; Stojanovska, L | 1 |
| Hu, Q; Zhang, XJ; Zhang, Y | 1 |
| Caballero-Hidalgo, A; Hernandez-Trujillo, Y; Macias-Reyes, A; Rodriguez-Esparragon, F; Rodriguez-Perez, JC | 1 |
| Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Rizos, CV | 1 |
9 review(s) available for rosiglitazone and Atherogenesis
| Article | Year |
|---|---|
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; Microcirculation; Preventive Medicine; Ramipril; Risk Factors; Rosiglitazone; Treatment Outcome | 2019 |
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.
Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Pharmacological approaches to improve endothelial repair mechanisms.
Topics: AC133 Antigen; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, CD; Antigens, CD34; Atherosclerosis; Benzopyrans; Carbazoles; Cardiovascular Diseases; Carvedilol; Cell Differentiation; Coronary Disease; Endothelium, Vascular; Erythropoietin; Ethanolamines; Glycoproteins; Hematopoietic Stem Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Nebivolol; Neovascularization, Physiologic; Oxidative Stress; Peptides; PPAR gamma; Propanolamines; Receptors, Angiotensin; Regeneration; Risk Factors; Rosiglitazone; Stem Cells; Thiazolidinediones; Vasodilator Agents | 2008 |
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Tunica Intima; Tunica Media; Vascular Resistance | 2009 |
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Topics: Adipokines; Animals; Atherosclerosis; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Weight Loss | 2007 |
The anti-atherogenic effects of thiazolidinediones.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypolipidemic Agents; Kidney; Lipid Metabolism; Models, Biological; Pioglitazone; Postmenopause; Rosiglitazone; Thiazolidinediones | 2007 |
Pleiotropic effects of thiazolidinediones.
Topics: Atherosclerosis; Body Fat Distribution; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
7 trial(s) available for rosiglitazone and Atherogenesis
| Article | Year |
|---|---|
Discordant effects of rosiglitazone on novel inflammatory biomarkers.
Topics: Aged; Atherosclerosis; Biomarkers; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lymphotoxin beta Receptor; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Rosiglitazone; Thiazolidinediones | 2013 |
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coron
Topics: Adult; Aged; Angina Pectoris; Atherosclerosis; Blood Glucose; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Postoperative Complications; Prospective Studies; Quebec; Rosiglitazone; Spain; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2009 |
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Risk; Rosiglitazone; Saphenous Vein; Thiazolidinediones | 2010 |
Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers.
Topics: Adult; Atherosclerosis; Biomarkers; C-Reactive Protein; E-Selectin; Endothelium, Vascular; Humans; Hypoglycemic Agents; Male; Rosiglitazone; Serum Amyloid A Protein; Thiazolidinediones; Vasculitis; Vasodilation | 2005 |
The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
Topics: Aged; Atherosclerosis; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Middle Aged; NF-kappa B; Oxidative Stress; PPAR gamma; Proteasome Endopeptidase Complex; Rosiglitazone; Superoxides; Thiazolidinediones; Ubiquitin | 2006 |
Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sweden; Thiazolidinediones; Tunica Intima | 2007 |
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Multivariate Analysis; Rosiglitazone; Thiazolidinediones; Tunica Intima; Tunica Media; Vasodilator Agents | 2007 |
48 other study(ies) available for rosiglitazone and Atherogenesis
| Article | Year |
|---|---|
Co-Delivery of Therapeutics and Bioactive Gas Using a Novel Liposomal Platform for Enhanced Treatment of Acute Arterial Injury.
Topics: Animals; Atherosclerosis; Drug Delivery Systems; Gases; Liposomes; Nitric Oxide; Rabbits; Rosiglitazone | 2023 |
Inhibition of perivascular mast cell activation is involved in the atheroprotective effect of rosiglitazone in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Cytokines; Hypoglycemic Agents; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Rosiglitazone | 2019 |
Chronological in vivo imaging reveals endothelial inflammation prior to neutrophils accumulation and lipid deposition in HCD-fed zebrafish.
Topics: Animals; Animals, Genetically Modified; Anti-Inflammatory Agents; Atherosclerosis; Cholesterol, Dietary; Disease Models, Animal; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hypercholesterolemia; Inflammation; Interleukin-1beta; Lipid Metabolism; Microscopy, Confocal; Neutrophil Infiltration; Plaque, Atherosclerotic; PPAR gamma; Rosiglitazone; Time Factors; Tumor Necrosis Factor-alpha; Zebrafish; Zebrafish Proteins | 2019 |
ERK1/2-PPARγ pathway is involved in
Topics: Apoptosis; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Chlamydophila pneumoniae; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Rosiglitazone; Scavenger Receptors, Class E; Signal Transduction; Umbilical Veins | 2020 |
Co-administration of conjugated linoleic acid and rosiglitazone increases atherogenic co-efficient and alters isoprenaline-induced vasodilatation in rats fed high fat diet.
Topics: Adrenergic beta-Agonists; Animals; Atherosclerosis; Blood Glucose; Body Weight; Diet, High-Fat; Isoproterenol; Linoleic Acids, Conjugated; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Vasodilation | 2018 |
Rosiglitazone modulates pigeon atherosclerotic lipid accumulation and gene expression in vitro.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Bird Diseases; Cardiotonic Agents; Columbidae; Disease Models, Animal; Gene Expression Regulation; Humans; Lipid Metabolism; Myocytes, Smooth Muscle; PPAR gamma; Proto-Oncogene Proteins c-myc; Rosiglitazone; Thiazolidinediones | 2014 |
Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cytoprotection; Drug Evaluation, Preclinical; Drug Synergism; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Male; Myocardium; Oxidative Stress; Pyrroles; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2014 |
Rosiglitazone impedes Porphyromonas gingivalis-accelerated atherosclerosis by downregulating the TLR/NF-κB signaling pathway in atherosclerotic mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Bacteroidaceae Infections; Cytokines; Down-Regulation; Lipids; Male; Mice, Knockout; NF-kappa B; Porphyromonas gingivalis; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Toll-Like Receptors | 2014 |
Rosiglitazone attenuates atherosclerosis and increases high-density lipoprotein function in atherosclerotic rabbits.
Topics: Animals; Aryldialkylphosphatase; Atherosclerosis; ATP Binding Cassette Transporter 1; Cholesterol; Disease Models, Animal; Enzyme Activation; Gene Expression; Hepatocytes; Hypoglycemic Agents; Lipids; Lipoproteins, HDL; Macrophages, Peritoneal; Male; Peroxidase; Rabbits; Rosiglitazone; Scavenger Receptors, Class B; Thiazolidinediones | 2015 |
Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Cell Line; Cholesterol; Cytokines; Fluorescein-5-isothiocyanate; Gadolinium; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Nanoparticles; Obesity; Paclitaxel; Phagocytosis; Phosphatidylethanolamines; Phosphatidylserines; Phospholipases A2; Polyethylene Glycols; Polystyrenes; Rosiglitazone; Tamoxifen; Thiazolidinediones | 2015 |
Adipose tissue deficiency results in severe hyperlipidemia and atherosclerosis in the low-density lipoprotein receptor knockout mice.
Topics: Adipose Tissue; Adiposity; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Disease Models, Animal; Genetic Predisposition to Disease; GTP-Binding Protein gamma Subunits; Heterotrimeric GTP-Binding Proteins; Hyperlipidemias; Hypolipidemic Agents; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Receptors, LDL; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Time Factors | 2016 |
Short-term treatment with a 2-carba analog of cyclic phosphatidic acid induces lowering of plasma cholesterol levels in ApoE-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Carotid Arteries; Cholesterol, LDL; Disease Models, Animal; Disease Progression; Inflammation; Lipid Metabolism; Macrophages; Mice; Mice, Inbred BALB C; Mice, Knockout; Phosphatidic Acids; PPAR gamma; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Triglycerides | 2016 |
DNMT1-PPARγ pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cytokines; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Humans; Hypoglycemic Agents; Inflammation; Macrophage Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; PPAR gamma; Promoter Regions, Genetic; Rosiglitazone; Thiazolidinediones | 2016 |
The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits.
Topics: Animals; Aorta; Atherosclerosis; Cholesterol, Dietary; Diet, Atherogenic; Glucose Tolerance Test; Hypoglycemic Agents; Immunohistochemistry; Male; Rabbits; Rosiglitazone; Thiazolidinediones; Tunica Intima | 2008 |
Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE-knockout mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Dietary Fats; Granulocyte-Macrophage Colony-Stimulating Factor; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Rosiglitazone; Simvastatin; Thiazolidinediones | 2008 |
A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling.
Topics: Animals; Atherosclerosis; Caffeic Acids; Cell Adhesion; Cells, Cultured; Cyclooxygenase 2; Disease Models, Animal; Endothelial Cells; Gene Expression Regulation; Inflammation; Male; Mice; Monocytes; NF-kappa B; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Phenylethyl Alcohol; Receptors, LDL; Rosiglitazone; Thiazolidinediones; Zinc | 2008 |
Antiatherosclerotic effect of farnesoid X receptor.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cardiovascular Agents; CD11b Antigen; CD36 Antigens; Chenodeoxycholic Acid; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Hyperlipidemias; Interleukin-1beta; Interleukin-6; Ligands; Lipids; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Toll-Like Receptor 4; Transcription Factors; Tumor Necrosis Factor-alpha | 2009 |
Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway.
Topics: Anilides; Atherosclerosis; Berberine; Cell Line; Chemokine CCL2; Humans; Hypoglycemic Agents; Interleukin-6; Lipoproteins, LDL; Macrophages; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2008 |
The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin.
Topics: Adiponectin; Animals; Atherosclerosis; Disease Models, Animal; Female; Inflammation Mediators; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred C57BL; Mice, Inbred MRL lpr; Mice, Knockout; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2009 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
Epstein-barr virus-induced gene-3 is expressed in human atheroma plaques.
Topics: Aorta; Atherosclerosis; Carotid Stenosis; Humans; Hypoglycemic Agents; Immunohistochemistry; Immunoprecipitation; Interleukins; Minor Histocompatibility Antigens; Myocytes, Smooth Muscle; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcription Factor RelA; Up-Regulation | 2009 |
A macrophage sterol-responsive network linked to atherogenesis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Foam Cells; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Macrophages; Male; Mice; Mice, Inbred C57BL; Proteins; Receptors, LDL; Rosiglitazone; Simvastatin; Sterols; Thiazolidinediones | 2010 |
Rosiglitazone, thiazolidinediones and atherosclerosis.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Leukocytes, Mononuclear; Nitric Oxide; Obesity; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Rosiglitazone and vascular injury in hypercholesterolemic rabbits: neointimal formation assessment.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Disease Models, Animal; Hypercholesterolemia; Iliac Artery; Male; Neointima; Rabbits; Random Allocation; Rosiglitazone; Thiazolidinediones | 2010 |
The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.
Topics: Adult; Aged; Atherosclerosis; Carotid Artery, Internal; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Risk; Rosiglitazone; Thiazolidinediones; Ultrasonography | 2010 |
Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cricetinae; Fatty Acids; Female; Fenofibrate; Hydrocarbons, Fluorinated; Hyperlipidemias; Liver X Receptors; Male; Mesocricetus; Orphan Nuclear Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Sulfonamides; Thiazolidinediones; Triglycerides | 2011 |
Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro.
Topics: Angiotensin II; Animals; Aortic Diseases; Atherosclerosis; Blotting, Western; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Hypercholesterolemia; Immunohistochemistry; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Radioimmunoassay; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2011 |
[PPARγ up-regulates TGFβ/smad signal pathway repressor c-Ski].
Topics: Anilides; Animals; Atherosclerosis; Cells, Cultured; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Proto-Oncogene Proteins; Rats; Rats, Wistar; Repressor Proteins; RNA, Messenger; Rosiglitazone; Signal Transduction; Smad Proteins; Thiazolidinediones; Transforming Growth Factor beta; Up-Regulation | 2011 |
Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
Topics: Atherosclerosis; Blood Coagulation Tests; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Malaysia; Male; Middle Aged; Plasminogen; Prothrombin; Rosiglitazone; Thiazolidinediones | 2011 |
Nrf2-dependent gene expression is affected by the proatherogenic apoE4 genotype-studies in targeted gene replacement mice.
Topics: Animals; Apolipoprotein E4; Atherosclerosis; Cell Line, Tumor; Cholesterol; Computational Biology; DNA Methylation; F2-Isoprostanes; Female; Gene Expression Regulation; Gene Targeting; Genotype; Glutathione Transferase; Heme Oxygenase-1; Humans; Liver; Mice; MicroRNAs; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Triglycerides | 2011 |
Opposing actions of rosiglitazone and resveratrol on mineralization in human vascular smooth muscle cells.
Topics: Apoptosis; Atherosclerosis; Caspases; Cell Differentiation; Cells, Cultured; Diabetes Mellitus; Humans; Hypoglycemic Agents; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Resveratrol; Rosiglitazone; Signal Transduction; Stilbenes; Thiazolidinediones; Up-Regulation | 2011 |
2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma.
Topics: Aorta; Atherosclerosis; Cell Cycle; Cell Proliferation; Chalcones; Drug Synergism; Gene Expression Regulation; Humans; Inflammation; Lipoproteins, LDL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2012 |
High-dose rosiglitazone is pro-atherogenic in cholesterol-fed rabbits.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Cholesterol, Dietary; Male; Rabbits; Rosiglitazone; Thiazolidinediones | 2012 |
The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes.
Topics: Atherosclerosis; Cell Line; Cell Separation; gag Gene Products, Human Immunodeficiency Virus; Gene Expression Regulation; GTP-Binding Proteins; HIV Antigens; HIV Infections; HIV-1; Humans; Inflammation; Isoxazoles; Janus Kinases; Lipid Metabolism; Lipopolysaccharide Receptors; Macrophages; Monocytes; Neoplasm Proteins; Neutralization Tests; Phenotype; Phosphorylation; PPAR gamma; Receptors for Activated C Kinase; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; Thiazolidinediones; Vaccination; Vidarabine | 2012 |
[Rosiglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice].
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Female; Hypoglycemic Agents; Macrophages; Male; Mice; Mice, Knockout; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2005 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Animal; Dyslipidemias; Female; Fenofibrate; Foam Cells; Homeostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Macrophages; Mice; Mice, Mutant Strains; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Triglycerides; Vasculitis | 2005 |
[PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?].
Topics: Albuminuria; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
[Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits].
Topics: Animals; Aorta; Atherosclerosis; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Fibrinolytic Agents; Hypercholesterolemia; Male; PPAR gamma; Rabbits; Random Allocation; Rosiglitazone; Thiazolidinediones; Tunica Intima | 2005 |
Stimulation of the peroxisome proliferator-activated receptor gamma (PPAR gamma) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy.
Topics: Adult; Aged; Atherosclerosis; Cohort Studies; Diabetes Mellitus, Type 2; Down-Regulation; Endothelial Cells; Female; Gene Expression Regulation; Humans; Interleukin-8; Male; Middle Aged; Monocytes; Peripheral Vascular Diseases; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2007 |
Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Cell Adhesion; Gemfibrozil; Gene Expression Profiling; Lipids; Male; Mice; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2007 |
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; England; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome.
Topics: Animals; Atherosclerosis; Blotting, Western; Low Density Lipoprotein Receptor-Related Protein-1; Marfan Syndrome; Mice; Mice, Transgenic; Microscopy, Fluorescence; Platelet-Derived Growth Factor; Rosiglitazone; Signal Transduction; Smad Proteins; Thiazolidinediones; Transforming Growth Factor beta; Tunica Intima | 2007 |
Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment.
Topics: Aorta; Atherosclerosis; Blotting, Western; Carotid Stenosis; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fenofibrate; Flow Cytometry; Humans; Ligands; Lipoproteins, LDL; Organ Culture Techniques; Rosiglitazone; Thiazolidinediones; Thrombomodulin; Ultraviolet Rays; Up-Regulation | 2008 |
Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cell Adhesion Molecules; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Disease Models, Animal; Down-Regulation; Endothelial Cells; Humans; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Umbilical Veins; Vascular Cell Adhesion Molecule-1; Vasculitis | 2008 |
[Rosiglitazone enhances the anti-atherosclerotic effects of peroxisome proliferator-activated receptor gamma1 gene transfer in apolipoprotein-knock out mice].
Topics: Animals; Apolipoproteins E; Atherosclerosis; Gene Transfer Techniques; Male; Mice; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transfection | 2007 |
Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.
Topics: Animals; Aryldialkylphosphatase; Atherosclerosis; Carboxylic Ester Hydrolases; CD36 Antigens; Cholesterol, Dietary; Gene Expression Regulation; Lipid Peroxidation; Lipid Peroxides; Lipids; Losartan; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2008 |